Skip to content
Back to meeting Original
ESMO - Eur. Oncology· @myESMO · X·· 2 days agoScore70

ARTEMIS-011

Body

#ESMO26: Antibody–drug conjugate (#ADC) risvutatug rezetecan provides the first progress in decades in #osteosarcoma, with significant improvement in progression-free survival versus chemotherapy in the ARTEMIS-011 #ClinicalTrial
#InsightsbyESMO
➡️ https://ow.ly/6zZX51000pg

178 views · 1 like · 0 reposts · 0 replies

Source: ESMO - Eur. Oncology · x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org

Disclaimer CBA Frontier Insights uses AI-assisted methods to aggregate, summarize, and analyze publicly accessible biopharmaceutical information. Content is provided for informational and educational purposes only and does not represent the official views of original sources or affiliated organizations. AI-generated content may contain errors; please verify important information against primary sources. Intellectual property rights remain with their respective owners. For copyright concerns or corrections, please contact us through the website’s feedback page.